secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-04-24T23:59:59+00:00
Accession:  0001193125-24-108717
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa prices $100M ADS offering at $9.25; pro forma cash enables runway into mid-2026
--------------------------------------------------------------------------------

- Priced 10,810,810 ADSs at $9.25/ADS; gross proceeds ~$100M. Close expected Apr 26, 2024.
- Net proceeds estimated at $93.5M (or $107.6M if over-allotment exercised).
- Underwriters granted 30-day option to purchase up to 1,621,621 additional ADSs.
- Preliminary cash, equivalents & ST investments at Mar 31, 2024: $230.2M.
- Proceeds to fund product candidate development and general corporate purposes; runway extended into mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312524108717/0001193125-24-108717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312524108717/d740386d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-108717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer